The National Comprehensive Cancer Network (NCCN) has updated and released the latest content of the NCCN guidelines for the clinical diagnosis and treatment of non-small cell lung cancer (NSCLC) in the version 1, 2022. Based on high-quality clinical evidence and the latest research progress of the diagnosis and treatment of NSCLC, the guidelines have been widely recognized and welcomed by clinicians around the world. Compared with the version 7, 2021, the new version has been updated and revised in some parts of chapters and sections, mainly focusing on targeted therapies and molecular testing. This article will interpret the updated therapy content of the new version.
Systematic review, a kind of higher-level evidence in evidence-based medicine, has a fully developed method system. However, it has some defects in the updating strategy. The living systematic review can effectively improve the timeliness of system reviews by periodically obtaining clinical evidences and updating the results of systematic reviews in a timely manner. This study briefly introduces the developing, characteristics, conditions, implementation and applications of living systematic reviews.
Based on new clinical evidence, the National Comprehensive Cancer Network (NCCN) annually updates and releases the "NCCN Guidelines for the Clinical Diagnosis and Treatment of Non-Small Cell Lung Cancer" which has become the reference for clinical diagnosis and treatment approved and complied by clinicians worldwide. On November 25, 2020, the latest 2021 V1 version of "NCCN Clinical Diagnosis and Treatment Guidelines for Non-Small Cell Lung Cancer" (hereinafter referred to as "Guidelines") was released. Compared with the 8th edition of the "Guidelines" in 2020, many updates focused on the progress of targeted and immunotherapy. This article will provide the interpretations of the updated therapy content of this edition of the guidelines.
With the rapid development of medicine and the emergence of new evidence, the formulation of living guidelines is significant in guiding clinical practice and providing timely and effective references for clinical workers. This article summarizes the status of living guidelines, and puts forward thoughts and suggestions on the challenges and opportunities of the development of living guidelines, in order to promote the development of living guidelines and provide a reference for guideline developers and users.
The accuracy of the clinical prediction model determines its extrapolation and application value. When the prediction model is applied to a new setting, the differences between the new population and the initially modeled population in terms of study time, population characteristics, region, and other factors could lead to a reduction in its predictive performance. Calibrating or updating the prediction model with appropriate statistical methods is important to improve the accuracy of the prediction model in new populations. The model updating methods mainly include regression coefficients updating, meta-model updating and dynamic model updating. However, due to the limitations of meta-model updating and dynamic model updating in practical applications, the regression coefficient updating method is still the most common method in model updating. This paper introducd several types of model updating methods, the regression coefficients updating methods for two common clinical prediction models based on Logistic regression and Cox regression, and provide corresponding R codes for reference of researchers.
The American Heart Association (AHA) released the 2017 American Heart Association Focused Update on Adult Basic Life Support and Cardiopulmonary Resuscitation Quality (2017 AHA guidelines update) in November 2017. The 2017 AHA guidelines update was updated according to the rules named " the update of the guideline is no longer released every five years, but whenever new evidence is available” in the 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. The updated content in this guideline included five parts: dispatch-assisted cardiopulmonary resuscitation (CPR), bystander CPR, emergency medical services - delivered CRP, CRP for cardiac arrest, and chest compression - to - ventilation ratio. This review will interpret the 2017 AHA guidelines update in detail.
Psoriatic arthritis (PsA) is a disease with heterogeneous manifestations in patients who have manifest or latent psoriasis. It comprises both musculoskeletal and non-musculoskeletal manifestations. Active chronic PsA is often accompanied by cardiovascular, psychological and metabolic complications. Although the quantity of disease-modifying antirheumatic drugs (DMARDs) indicated for PsA has increased, clinicians still require some guidance in decision-making. Based on the latest evidence-based research results, the European League Against Rheumatism (EULAR) in 2019 developed the recommendations for the pharmacological management of PsA updated in 2015 with new recommendations. This paper interprets the update contents of the guideline to provide references for the clinical treatment of PsA.
Upper gastrointestinal tract cancers originating in the esophagus or esophagogastric junction constitute a major global health problem. On February 28, 2023, National Comprehensive Cancer Network (NCCN) released the clinical practice guidelines for esophageal and esophagogastric junction cancer (version 1.2023). This article will interpret the main updates related to the treatment and follow-up in this version compared to the version 5.2022, in order to provide the Chinese clinicians a better basis and reference for the diagnosis and treatment of the diseases.